Skip to content
10-Q

Quarterly Report

ANAVEX LIFE SCIENCES CORP. AVXL

0001731122-26-000200

← back to feed
Filed
Feb 9, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Feb 9, 2026 92.67M sh
Shares Diluted Q1 2026 · Dec 31, 2025 89.03M sh
Shares Diluted Q1 2026 · Dec 31, 2024 84.81M sh
Operating Cash Flow Q1 2026 · Dec 31, 2025 −$7.15M
Operating Cash Flow Q1 2026 · Dec 31, 2024 −$12.12M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $131.75M
Cash And Equivalents Q1 2026 · Sep 30, 2025 $102.58M
Stockholders Equity Q1 2026 · Dec 31, 2025 $126.62M
Stockholders Equity Q1 2026 · Sep 30, 2025 $94.87M
Stockholders Equity Q1 2026 · Dec 31, 2024 $110.92M
Stockholders Equity Q1 2026 · Sep 30, 2024 $120.26M
Total Liabilities Q1 2026 · Dec 31, 2025 $6.37M
Total Liabilities Q1 2026 · Sep 30, 2025 $8.95M
Total Assets Q1 2026 · Dec 31, 2025 $132.99M
Total Assets Q1 2026 · Sep 30, 2025 $103.82M
Eps Diluted Q1 2026 · Dec 31, 2025 −$0.06
Eps Diluted Q1 2026 · Dec 31, 2024 −$0.14
Eps Basic Q1 2026 · Dec 31, 2025 −$0.06
Eps Basic Q1 2026 · Dec 31, 2024 −$0.14
Sga Expense Q1 2026 · Dec 31, 2025 $2.13M
Sga Expense Q1 2026 · Dec 31, 2024 $3.15M
Rd Expense Q1 2026 · Dec 31, 2025 $4.66M
Rd Expense Q1 2026 · Dec 31, 2024 $10.45M
Net Income Q1 2026 · Dec 31, 2025 −$5.68M
Net Income Q1 2026 · Dec 31, 2024 −$12.11M
Operating Income Q1 2026 · Dec 31, 2025 −$6.78M
Operating Income Q1 2026 · Dec 31, 2024 −$13.59M